Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma

被引：1

作者：

Yuen, AR

Higgins, JP

Baker, R

Kamel, OW

Warnke, RA

Knox, SJ

机构：

[1] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA

[2] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA

[3] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA

来源：

HUMAN PATHOLOGY | 2003年 / 34卷 / 04期

关键词：

ferritin; Kaposi's sarcoma; Hodgkin's disease; hepatocellular carcinoma; antiferrtin antibody;

D O I：

10.1053/hupa.2003.62

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The immunotherapeutic treatment of cancers using antibodies (naked or conjugated to a drug, toxin, or radionuclide) relies upon the preferential expression of a targeted antigen on the cancer cell compared to normal tissues. Polyclonal antiferritin antisera have shown selective distribution and therapeutic efficacy when radiolabeled in Hodgkin's disease and hepatoma. In this immunohistochemical study, we investigated the distribution of ferritin in tumors from 6 patients with Kaposi's sarcoma, 12 patients with Hodkgin's disease, and 9 patients with hepatoma, as well as in selected normal tissues. We found that the monoclonal antiferritin antibody binds primarily to histiocytes in samples from Kaposi's sarcoma and Hodgkin's disease. One hepatocellular carcinoma showed diffuse cytoplasmic staining with ferritin. Deposition of the monoclonal antibody was not detectable in the remaining hepatocellular carcinoma samples.

引用

页码：381 / 384

页数：4

共 9 条

[1] ADVANTAGES OF DETECTING MONOCLONAL-ANTIBODY BINDING TO TISSUE-SECTIONS WITH BIOTIN AND AVIDIN REAGENTS IN COPLIN JARS [J].

BINDL, JM ;

WARNKE, RA .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1986, 85 (04) :490-493

[2]

HOOD AB, 1988, ANTIB IMMUNOCONJUG R, V1, P189

[3]

KLEIN JL, 1989, CANCER RES, V49, P6383

[4] A RANDOMIZED PROSPECTIVE TRIAL COMPARING FULL DOSE CHEMOTHERAPY TO I-131 ANTIFERRITIN - AN RTOG STUDY [J].

ORDER, S ;

PAJAK, T ;

LEIBEL, S ;

ASBELL, S ;

LEICHNER, P ;

ETTINGER, D ;

STILLWAGON, G ;

HERPST, J ;

HAULK, T ;

KOPHER, K ;

FRAZIER, C ;

KLEIN, J .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (05) :953-963

[5] I-131 ANTIFERRITIN, A NEW TREATMENT MODALITY IN HEPATOMA - A RADIATION-THERAPY-ONCOLOGY-GROUP STUDY [J].

ORDER, SE ;

STILLWAGON, GB ;

KLEIN, JL ;

LEICHNER, PK ;

SIEGELMAN, SS ;

FISHMAN, EK ;

ETTINGER, DS ;

HAULK, T ;

KOPHER, K ;

FINNEY, K ;

SURDYKE, M ;

SELF, S ;

LEIBEL, S .

JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (12) :1573-1582

[6]

Torti S V, 1994, Adv Inorg Biochem, V10, P119

[7] PHASE-I-II STUDIES OF YTTRIUM-LABELED ANTIFERRITIN TREATMENT FOR END-STAGE HODGKINS-DISEASE, INCLUDING RADIATION-THERAPY-ONCOLOGY-GROUP-87-01 [J].

VRIESENDORP, HM ;

HERPST, JM ;

GERMACK, MA ;

KLEIN, JL ;

LEICHNER, PK ;

LOUDENSLAGER, DM ;

ORDER, SE .

JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (06) :918-928

[8]

Vriesendorp HM, 1999, CLIN CANCER RES, V5, p3324S

[9] SELECTION OF REAGENTS FOR HUMAN RADIOIMMUNOTHERAPY [J].

VRIESENDORP, HM ;

QUADRI, SM ;

STINSON, RL ;

ONYEKWERE, OC ;

SHAO, Y ;

KLEIN, JL ;

LEICHNER, PK ;

WILLIAMS, JR .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 22 (01) :37-45

← 1 →